Travere Therapeutics (NASDAQ:TVTX) Insider Elizabeth Reed Sells 2,076 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Elizabeth Reed sold 2,076 shares of the company’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $91,240.20. Following the completion of the transaction, the insider owned 105,211 shares in the company, valued at approximately $4,624,023.45. The trade was a 1.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Trading Down 0.2%

NASDAQ TVTX opened at $44.70 on Thursday. Travere Therapeutics, Inc. has a 12 month low of $13.88 and a 12 month high of $48.61. The company’s 50-day moving average price is $32.59 and its 200-day moving average price is $32.83. The stock has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The company had revenue of $127.20 million during the quarter, compared to analyst estimates of $136.23 million. During the same period in the prior year, the firm earned ($0.47) earnings per share. The firm’s revenue for the quarter was up 55.6% compared to the same quarter last year. Equities research analysts forecast that Travere Therapeutics, Inc. will post -0.16 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating for the company in a research note on Wednesday, March 25th. Wells Fargo & Company upped their price objective on shares of Travere Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research note on Wednesday. Wedbush upped their price objective on shares of Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research note on Tuesday. Citigroup upped their price objective on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, Piper Sandler raised shares of Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price target for the company in a research report on Tuesday, April 14th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $47.83.

Institutional Trading of Travere Therapeutics

Hedge funds have recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in shares of Travere Therapeutics during the second quarter valued at about $33,000. Fifth Third Bancorp purchased a new stake in shares of Travere Therapeutics during the first quarter valued at about $35,000. First Horizon Corp purchased a new stake in shares of Travere Therapeutics during the third quarter valued at about $36,000. State of Wyoming purchased a new stake in shares of Travere Therapeutics during the fourth quarter valued at about $37,000. Finally, Torren Management LLC purchased a new stake in shares of Travere Therapeutics during the fourth quarter valued at about $38,000.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year‑over‑year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long‑term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre‑arranged Rule 10b5‑1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500‑share sale) can create short‑term selling pressure or investor concern. Example SEC filing: CEO Form 4

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.